In addition, the humanized anti-NKG2A antibody monalizumab, which blocks NKG2A–HLA-E interaction, enhanced NK cell activity against various tumor cells; its clinical trials are ongoing [166] (Table 1). This evidence concerns the gene KLRC1 and neoplasm.